How do genetic biomarkers correlate with ADHD brain volume changes?

PostedOctober 8, 2025

UpdatedOctober 10, 2025

ByMy Patient Advice

Author: Victoria Rowe, MSc | Reviewed by: Dr. Rebecca Fernandez, MBBS

ADHD brain volume genetics is an area of growing research that aims to understand how specific genetic biomarkers correlate with changes in brain volume, particularly in regions linked to attention, executive function, and behavioural control. Studies have shown that individuals with ADHD often have differences in brain volume, especially in cortical and subcortical regions, and these changes are influenced by genetic factors. By examining these correlations, researchers are uncovering new insights into the biological basis of ADHD and how genetics affect brain structure.

Genetic Influence on Brain Volume

Genetic influence on brain volume in ADHD affects regions like the prefrontal cortex and basal ganglia, which are crucial for attention, planning, and impulse control.

Cortical Volume

In individuals with ADHD, cortical volume of the thickness and size of the brain’s outer layer, which is involved in complex cognitive tasks is often reduced. Genetic factors, such as variations in the DAT1 (dopamine transporter) and DRD4 (dopamine receptor) genes, have been linked to these changes in the cortex, particularly in the prefrontal cortex. This region is crucial for attention, impulse control, and working memory, and its reduced volume could explain the cognitive difficulties seen in ADHD.

Subcortical Regions

In addition to cortical changes, ADHD is also associated with altered subcortical brain regions, including the striatum, basal ganglia, and cerebellum. These regions are involved in reward processing, movement control, and emotional regulation, which are often impaired in ADHD. Genetic variants in genes like COMT (catechol-O-methyltransferase) and SNAP-25 (synaptosomal-associated protein) can influence the volume and function of these subcortical structures, contributing to the behavioural symptoms of ADHD.

Why Genetic Biomarkers Matter for ADHD Brain Volume Changes

Genetic biomarkers matter for ADHD brain volume changes because they help explain individual differences in brain development and guide targeted treatment strategies.

Biomarkers for ADHD

Identifying genetic biomarkers associated with brain volume changes could lead to more precise diagnostics. By linking specific ADHD risk alleles to structural brain differences, clinicians could use these biomarkers to better understand individual cases of ADHD, leading to more personalised treatment approaches.

Personalised Treatment

Understanding how genetic factors influence brain volume could help tailor ADHD treatments. For example, individuals with specific genetic profiles might benefit from interventions targeting brain areas that show volume deficits, such as dopamine-modulating medications or therapies that support cognitive control.

Tracking Treatment Response

Genetic biomarkers related to brain volume changes could also serve as tools to monitor the effectiveness of ADHD treatments. Tracking how brain volume in key regions responds to treatment could offer insight into long-term improvements in brain function and symptom management.

ADHD brain volume genetics offers valuable insights into how genetic factors influence brain structure and function, providing a clearer understanding of the neurobiological roots of ADHD. These findings open the door to more personalised treatments and more accurate diagnostic tools.

Visit providers like ADHD Certify for personal consultations that incorporate genetic biomarkers and brain volume insights in ADHD care.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Genetic studies and biomarkers.

Victoria Rowe, MSc

Author

Victoria Rowe is a health psychologist with a Master’s in Health Psychology and a BS in Applied Psychology. She has experience as a school psychologist, conducting behavioural assessments, developing individualized education plans (IEPs), and supporting children’s mental health. Dr. Rowe has contributed to peer-reviewed research on mental health, including studies on anxiety disorders and the impact of COVID-19 on healthcare systems. Skilled in SPSS, Minitab, and academic writing, she is committed to advancing psychological knowledge and promoting well-being through evidence-based practice.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Rebecca Fernandez, MBBS

Reviewer

Dr. Rebecca Fernandez is a UK-trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence-based approaches such as CBT, ACT, and mindfulness-based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewer's privacy.